00:21 , Aug 10, 2018 |  BC Week In Review  |  Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Aug. 8 after reporting narrowing U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower...
21:35 , Aug 8, 2018 |  BC Extra  |  Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Wednesday after reporting declining U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower U.S....
17:59 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Neuraly raises $36M series A to develop microglia-targeted PD candidate

Neurodegeneration company Neuraly Inc. (Germantown, Md.) launched July 18 with a tranched $36 million series A round led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna Investment, Geon...
20:36 , Jul 18, 2018 |  BC Extra  |  Financial News

Neuraly debuts with $36M to target neurodegenerative diseases

Neurodegeneration company Neuraly Inc. (Germantown, Md.) launched Wednesday with a tranched $36 million series A round led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna Investment, Geon Investment...
19:27 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Xeris' G-Pen increases plasma glucose in Phase III pediatric hypoglycemia

Xeris Pharmaceuticals Inc. (NASDAQ:XERS) said its G-Pen glucagon injection rescue pen significantly increased mean plasma glucose levels within 30 minutes by at least 25 mg/dL in all patients in a Phase III trial to treat...
19:25 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Xeris' G-Pen similar to standard kit in Phase III hypoglycemia

Xeris Pharmaceuticals Inc. (NASDAQ:XERS) said its G-Pen glucagon injection rescue pen had comparable efficacy to a standard glucagon emergency kit in a double-blind, crossover Phase III trial to treat severe hypoglycemia in adult Type I...
16:44 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

AZ's MEDI0382 reduces glucose and body weight in Phase IIa for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said once-daily 200 µg subcutaneous MEDI0382 significantly reduced glucose area under the curve (AUC) from 0-4 hours after a Mixed Meal Tolerance Test (MMTT) (32.8% vs....
14:48 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Zafgen's ZGN-1061 meets in Phase II for Type II diabetes

Zafgen Inc. (NASDAQ:ZFGN) said the 0.9 mg dose of subcutaneous ZGN-1061 every three days met the primary endpoint in a Phase II trial to treat Type II diabetes in patients failing multiple other antidiabetic agents....
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
18:27 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Novo's oral GLP-1 analog meets primary in Phase IIIa trials compared with approved therapies

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing HbA1c and led to greater body weight reductions than both drugs in a...